{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:32:09Z","timestamp":1788849129863,"version":"build-2803163510"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Carcinosarcoma of the ovary is a rare pathological type of ovarian cancer that is highly aggressive and occurs most frequently in the female reproductive tract at the site of the uterus. Herein, we explore the clinicopathological features, diagnosis, differential diagnosis, and treatment options for carcinosarcoma of the ovary.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed the clinical data of a case of carcinosarcoma, observed its histological morphology and immunohistochemical characteristics, detected the homologous recombination repair deficiency gene mutation, and reviewed the relevant literature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A 76-year-old menopausal woman visited our hospital because of abdominal distension, difficulty in urination, and constipation. Ultrasonography demonstrated abnormalities in the uterus and pelvic cavity, suggesting that the patient should undergo surgery. Immunohistochemical findings of carcinosarcoma of the right ovary were as follows: CK fraction (+), vimentin fraction (+), CK5\/6 foci (+), p16 (+), p53 in approximately 70% (+), WT-1 foci (+), ER foci (+), PR part (+), Her-2 (1+), CK7 fraction (+), CK20 foci (+), CD99 fraction (+), CD10 fraction (+), CD56 foci (+), c-kit foci (+), SMA part (+), desmin foci (+), PD-L1 (-), SALL4 (-), OCT3\/4 (-), p63 (-), p40 (-), D2-40 (-), inhibin (-), PLAP (-), CD30 (-), and Ki67 hotspot in approximately 80% (+). The patient underwent tumor cytoreduction and adjuvant chemotherapy. Currently, she is being followed up for 16 months and has a good general condition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The diagnosis of carcinosarcoma relies on histopathological examination and differentiation of carcinosarcoma from immature teratoma. The current therapeutic regimen for carcinosarcoma is still based on tumor cytoreduction and platinum-containing chemotherapy; research on targeted therapy is still in progress.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1278300","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T07:19:54Z","timestamp":1697613594000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Carcinosarcoma of the ovary: a case report and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Jian","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6089","DOI":"10.3390\/ijerph20126089","article-title":"Clinical challenges in the management of Malignant ovarian germ cell tumours","volume":"20","author":"Saani","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.03.002","article-title":"Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma","volume":"133","author":"Doo","year":"2014","journal-title":"Gynecologic Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ygyno.2016.04.025","article-title":"Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A national cancer database analysis","volume":"142","author":"Rauh-Hain","year":"2016","journal-title":"Gynecologic Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jogc.2023.02.002","article-title":"Erratum dans la directive clinique \u00ab N\u00b0 250-infection r\u00e9currente des voies urinaires \u00bb [J obstet gynaecol can 2017;39(10):E464-E474]","volume":"45","author":"Epp","year":"2023","journal-title":"J obstetr gynaecol Canada: JOGC = J d\u2019obstetrique gynecologie du Canada: JOGC"},{"key":"B5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4103\/0973-1482.80460","article-title":"Malignant mixed mullerian tumor of broad ligament with synchronous ovarian and endometrial carcinoma: A rare association","volume":"7","author":"Arora","year":"2011","journal-title":"J Cancer Res Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-017-1153-7","article-title":"Biphasic Malignant tumours of the abdominal cavity","volume":"22","author":"Almond","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20256","article-title":"Carcinosarcoma of the ovary: 19 years of prospective data from a single center","volume":"100","author":"Brown","year":"2004","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.02.016","article-title":"Survival of women diagnosed with Malignant, mixed mullerian tumors of the ovary (Ommmt)","volume":"93","author":"Barnholtz-Sloan","year":"2004","journal-title":"Gynecologic Oncol"},{"key":"B9","first-page":"1","article-title":"Presence of both mesenchymal and carcinomatous features in an in-vitro model of ovarian carcinosarcoma derived from patients\u2019 Ascitic fluid","volume":"9","author":"Shariftabrizi","year":"2015","journal-title":"Int J hematol-oncol Stem Cell Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1999.5681","article-title":"Carcinosarcoma of the ovary in a patient with a germline brca2 mutation: evidence for monoclonal origin","volume":"76","author":"Sonoda","year":"2000","journal-title":"Gynecologic Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/1066896919838347","article-title":"Ovarian carcinosarcoma and concurrent serous tubal intraepithelial carcinoma with next-generation sequencing suggesting an origin from the fallopian tube","volume":"27","author":"See","year":"2019","journal-title":"Int J Surg Pathol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/OGX.0b013e3181b8aff3","article-title":"Carcinosarcoma of the ovary a review","volume":"64","author":"Cantrell","year":"2009","journal-title":"Obstetrical gynecological survey"},{"key":"B13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.critrevonc.2018.12.006","article-title":"Ovarian carcinosarcoma: current developments and future perspectives","volume":"134","author":"Boussios","year":"2019","journal-title":"Crit Rev oncol\/hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.4103\/0973-1482.147390","article-title":"Carcinosarcoma of ovary with its various immunohistochemical expression: report of a rare case","volume":"11","author":"Dasgupta","year":"2015","journal-title":"J Cancer Res Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12885-018-4082-6","article-title":"Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: A single institution case series and review of the literature","volume":"18","author":"Brackmann","year":"2018","journal-title":"BMC Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-017-1215-x","article-title":"Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment","volume":"23","author":"Yalcin","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170879","article-title":"Clinical significance of programmed death ligand\u22121 and intra-tumoral cd8+ T lymphocytes in ovarian carcinosarcoma","volume":"12","author":"Zhu","year":"2017","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2008.00757.x","article-title":"Angiogenesis and expression of angiogenic agents in uterine and ovarian carcinosarcomas","volume":"116","author":"N\u00e4yh\u00e4","year":"2008","journal-title":"APMIS: Acta pathologica microbiologica immunologica Scandinavica"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30591","article-title":"Kras mutation coupled with P53 loss is sufficient to induce ovarian carcinosarcomas in mice","volume":"140","author":"Tang","year":"2017","journal-title":"Int J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s13224-012-0284-z","article-title":"Malignant mixed mullerian tumor of the ovary","volume":"64","author":"Gore","year":"2014","journal-title":"J obstetr gynaecol India"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2002.6645","article-title":"Paclitaxel and platinum chemotherapy for Malignant mixed m\u00fcllerian tumors of the ovary","volume":"85","author":"Duska","year":"2002","journal-title":"Gynecologic Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/s1028-4559(10)60016-2","article-title":"Primary Malignant mixed m\u00fcllerian tumor of the ovary","volume":"49","author":"Chiu","year":"2010","journal-title":"Taiwanese J obstetr gynecol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-011-1845-6","article-title":"Malignant mixed mullerian tumor of the ovary with two cases and review of the literature","volume":"283","author":"Duman","year":"2011","journal-title":"Arch gynecol obstetr"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jscr\/rjaa406","article-title":"Ovarian Malignant mixed m\u00fcllerian tumor: A rare case report from Tanzania","volume":"2020","author":"Pallangyo","year":"2020","journal-title":"J Surg Case Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/26330040221107389","article-title":"Primary ovarian Malignant mixed m\u00fcllerian tumor: A rare case report","volume":"3","author":"Jagtap","year":"2022","journal-title":"Ther Adv rare Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1515\/prilozi-2017-0010","article-title":"Extremely locally advanced ovarian Malignant mixed mullerian tumor in 37-years-old female","volume":"38","author":"Jota","year":"2017","journal-title":"Prilozi (Makedonska akademija na naukite i umetnostite Oddelenie za medicinski nauki)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/612824","article-title":"Serous ovarian carcinoma recurring as Malignant mixed mullerian tumor","volume":"2015","author":"Hale","year":"2015","journal-title":"Case Rep obstetr gynecol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0b013e31817b06c7","article-title":"Malignant m\u00fcllerian mixed tumor of the ovary associated with yolk sac tumor, neuroepithelial and trophoblastic differentiation (Teratoid carcinosarcoma)","volume":"27","author":"Garc\u00eda-Galvis","year":"2008","journal-title":"Int J gynecological Pathol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-010-1591-1","article-title":"Ovarian Malignant mullerian mixed tumor (Heterologous) whose epithelial component is composed predominantly of signet ring cell carcinoma","volume":"283","author":"Terada","year":"2011","journal-title":"Arch gynecol obstetr"},{"key":"B30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1006\/gyno.2000.5956","article-title":"Chemotherapy for Malignant mixed m\u00fcllerian tumors of the ovary","volume":"79","author":"Sit","year":"2000","journal-title":"Gynecologic Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2018.02.037","article-title":"Gas gangrene of Malignant mixed mullerian tumor of ovary caused by clostridium perfringens","volume":"54","author":"Musikatavorn","year":"2018","journal-title":"J Emergency Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2006.00281.x","article-title":"Malignant mixed m\u00fcllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy","volume":"16","author":"Mok","year":"2006","journal-title":"Int J gynecological Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0756.2010.01238.x","article-title":"Malignant mixed m\u00fcllerian tumor with Malignant neuroectodermal components (Teratoid carcinosarcoma) of the ovary: report of a case with clinicopathologic findings","volume":"36","author":"Matsuura","year":"2010","journal-title":"J obstetr gynaecol Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1179\/joc.1998.10.5.418","article-title":"Prolonged survival of stage iv Malignant mixed m\u00fcllerian tumor of the ovary after carboplatin, mesna, ifosfamide, and cis-platin chemotherapy: case report","volume":"10","author":"Di Vagno","year":"1998","journal-title":"J chemother (Florence Italy)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0b013e318264aece","article-title":"Ovarian carcinosarcoma associated with bilateral tubal intraepithelial carcinoma: A case report","volume":"32","author":"Brustmann","year":"2013","journal-title":"Int J gynecological Pathol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-009495","article-title":"Bilateral ovarian Malignant mixed mullerian tumour: A rare entity","volume":"2013","author":"Kumar","year":"2013","journal-title":"BMJ Case Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.5812\/ircmj.14919","article-title":"Prolonged survival of a patient with pelvic recurrence of ovarian Malignant mixed mullerian tumor after chemoradiotherapy","volume":"16","author":"Homaei Shandiz","year":"2014","journal-title":"Iranian Red Crescent Med J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/403431","article-title":"Advanced mesodermal (M\u00fcllerian) adenosarcoma of the ovary: metastases to the lungs, mouth, and brain","volume":"2015","author":"Daskalaki","year":"2015","journal-title":"Case Rep Surg"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900415)65:8<1753::aid-cncr2820650816>3.0.co;2-r","article-title":"Two homologous mixed m\u00fcllerian tumor lines of the ovary and their characteristics","volume":"65","author":"van Haaften-Day","year":"1990","journal-title":"Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0b013e3181f9eba5","article-title":"Malignant melanoma arising in an ovarian carcinosarcoma: case report and review of the literature","volume":"30","author":"Roma","year":"2011","journal-title":"Int J gynecological Pathol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1999.5653","article-title":"Alpha-fetoprotein production by a Malignant mixed m\u00fcllerian tumor of the ovary","volume":"77","author":"Rebischung","year":"2000","journal-title":"Gynecologic Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0b013e3181bd413c","article-title":"Ovarian Malignant mixed mesodermal tumor with neuroectodermal differentiation: A multifaceted evaluation","volume":"29","author":"Mott","year":"2010","journal-title":"Int J gynecological Pathol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"8113","DOI":"10.3390\/ijerph19138113","article-title":"Epithelial ovarian cancer: providing evidence of predisposition genes","volume":"19","author":"Shah","year":"2022","journal-title":"Int J Environ Res Public Health"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1278300\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T07:19:58Z","timestamp":1697613598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1278300\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":43,"alternative-id":["10.3389\/fonc.2023.1278300"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1278300","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,18]]},"article-number":"1278300"}}